Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
NAUT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $3.09
Previous CloseN/A
Volume36.21K
Average Volume (3M)166.78K
Market Cap
$98.65M
Enterprise Value$111.92M
Total Cash (Recent Filing)$25.73M
Total Debt (Recent Filing)$33.62M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Apr 29, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding126,148,470
10 Day Avg. Volume140,258
30 Day Avg. Volume166,782
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$2.75Price Target Upside271.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Nautilus Biotechnolgy News
PremiumCompany Announcements
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Nautilus Biotechnology Reports 2024 Financial Results
PremiumCompany Announcements
Nautilus Biotechnology Announces Board Changes for 2025
PremiumCompany Announcements
Nautilus Biotechnology Announces Board Member Departures---
Bulls Say, Bears Say
Bulls Say
Cash ManagementOngoing cash management efforts are encouraging, as well as the progress towards a differentiated proteomics offering.
Cost ManagementCost management and a 16% reduction in force should enable the cash runway to extend to 2027.
Technology DevelopmentThe company remains highly confident in its technology, and while disappointing, they feel they are making progress and taking the necessary steps to ensure a successful product commercialization.
Bears Say
Commercial Launch DelayCommercial launch now expected in late-2026, delayed from late 2025, due to modifications needed on the assay configuration and surface chemistry.
Internal MilestonesThe company was behind on internal milestones with respect to a major broadscale goal of quantifying a significant number of proteins from a complex sample.
Stock Price ImpactNAUT traded down nearly (20%) after another commercial launch timeline delay, this one a push out to late 2026.
---
Ownership Overview
42.96% Insiders
3.74% Mutual Funds
0.02% Other Institutional Investors
49.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.66 and its highest was $3.09 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $98.65M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Apr 29, 2025 which is in 4 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Feb 27, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.013.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.15.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 126,148,470 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went down -18.182%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
---
Nautilus Biotechnolgy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (271.62% Upside)
$2.75 (271.62% Upside)
Hedge Fund Trend
Increased
By 96.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $76.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.20%
12-Months-Change
Fundamentals
Return on Equity
-29.86%
Trailing 12-Months
Asset Growth
-20.56%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology (NAUT) is a pioneering company in the biotechnology sector, focused on revolutionizing the field of proteomics. The company's core product is its proprietary platform designed to comprehensively analyze and quantify proteins with unprecedented sensitivity and scale. This breakthrough technology aims to accelerate biomedical research and development, enabling deeper insights into the proteome that can drive advancements in drug discovery, diagnostics, and personalized medicine.
---
NAUT Company Deck
---
NAUT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant scientific advancements and partnerships in the proteomics field, with financial strategies extending the company's cash runway. However, a major delay in the product launch timeline and increased net losses weigh heavily on the company's near-term outlook.Read More>---
NAUT Stock 12 Month Forecast
Average Price Target
$2.75
▲(271.62% Upside)
Technical Analysis
Best Analysts Covering NAUT
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-45.72%
reiterated a buy rating 2 months ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -45.72% per trade.
---